Data sourced from SEC EDGAR filings and third-party price providers. Scores, valuations, and metrics are algorithmic estimates. This is not investment advice. See our Terms and Methodology.
/
Data sourced from SEC EDGAR filings and third-party price providers. Scores, valuations, and metrics are algorithmic estimates. This is not investment advice. See our Terms and Methodology.
XVIVO Perfusion AB is a medical technology company dedicated to extending the life of major organs through innovative preservation and perfusion technologies, enabling transplant teams worldwide to save more lives. Founded in 1998 and headquartered in Gothenburg, Sweden, it leads globally in lung preservation with products like PERFADEX Plus for cold storage and XPS with STEEN Solution for machine perfusion. The company is the European leader in liver perfusion via Liver Assist and has launched transportable kidney devices using its proprietary Hypothermic Oxygenated Perfusion (HOPE) method, which extends organ viability, reduces complications, and supports longer transport times. XVIVO is introducing heart preservation technology, anticipated for European launch in 2025, comprising machines, disposables, and specialized solutions. Its offerings span thoracic and abdominal machine perfusion, organ recovery services with 24/7 teams, and advanced communication software like FlowHawk. Backed by clinical evidence from journals such as The Lancet and New England Journal of Medicine, XVIVO addresses the global organ shortage—where only 10% of demand is met—by improving marginal organ utilization, generating cost savings for healthcare systems, and fostering growth in transplantation across lung, heart, liver, and kidney sectors.
kr 256.40
kr 2.60 (-1.00%)
Live · 10:06 PM · Twelve Data
11.34% operating margin is respectable but not wide. ROIC at 2.71%. Suggests the business covers its cost of capital, but doesn't point to a wide moat.
Revenue declined 1.2% YoY. The question is whether this is cyclical or a structural shift.
At 110x earnings, the current multiple leaves limited room for execution misses or growth deceleration. Negative free cash flow of -kr 152M. The business is consuming cash, not generating it.
109.6x earnings. The market is pricing in years of above-average growth. If that thesis breaks, downside from multiple compression alone could be 30%+. This is a stock where you're paying for the future, not the present.
Based on TTM earnings · Diluted shares
Profitability & Returns
Revenue (TTM)
kr 835M
▼ -1.2% YoY
Net Income (TTM)
kr 74M
▼ -85.4% YoY
Op. Margin
11.68%
▲ +0.5pp YoY
ROIC
2.71%
▼ -1.0pp YoY
Cash Flow & Balance Sheet
FCF (TTM)
-kr 71M
▼ -85.5% YoY
Op. Cash Flow (TTM)
kr 65M
▼ -112.4% YoY
Net Debt
-kr 167M
Net Cash Position
Cash & Equiv.
kr 292M
3Y CAGR: +25.1%
Continue Research
At a P/E of 109.6, XVIVO Perfusion AB (XVIVO.XSTO)'s valuation is best read against its own history, its peers, and the growth its price implies. A high multiple is not the same as overvalued: fast-growing, high-quality businesses can deserve a premium. See the general approach in how to tell if a stock is overvalued.
On quality, XVIVO Perfusion AB scores 44/100 on Intrinsiqq's quality scorecard, weighing growth, margins, returns on capital, share count, and balance-sheet strength. All figures are computed from SEC filings; read the full . This is analysis, not investment advice.
XVIVO Perfusion AB scores 44 out of 100 on Intrinsiqq's quality score, a weighted blend of 7 metrics each scored 0 to 100, which makes it a mixed business on these measures. Recent fundamentals include a 11.7% operating margin and a 2.7% return on invested capital. The score weighs revenue and free-cash-flow growth, operating margins, return on invested capital, share-count change, and balance-sheet strength, all computed from SEC filings, not opinion. Because valuation only means something relative to quality, the full metric-by-metric breakdown is on the quality scorecard.
That depends on valuation and quality together, not either alone. you should weigh XVIVO.XSTO's valuation and scores 44/100 on quality (mixed). A cheap price is only a bargain if the business is durable, and a premium can be justified by genuine quality, so the two questions, "is it cheap?" and "is it good?", only make sense side by side. Read the valuation against the quality scorecard, run the DCF on your own assumptions, and decide for yourself. This is analysis from SEC filings, not investment advice.